SCHEMBL31341963

SCHEMBL31341963

Cc1c(F)ccc(F)c1-c1c(C(=O)O)c[nH]c1C(=O)c1ccc(CCCOCCO)cc1

nearest known ligand 0.33

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ DHODH Q02127 1/20 0.33
▸ PRKAB2 O43741 5/20 0.33
▸ PRKAG1 P54619 5/20 0.33
▸ PRKAA2 P54646 5/20 0.33
▸ PRKAA1 Q13131 5/20 0.33
▸ PRKAG3 Q9UGI9 5/20 0.33
▸ PRKAG2 Q9UGJ0 5/20 0.33
▸ PRKAB1 Q9Y478 5/20 0.33
▸ RARB P10826 4/20 0.32
▸ TTR P02766 1/20 0.32
▸ ALB P02768 1/20 0.32
▸ RARA P10276 2/20 0.31
▸ RARG P13631 1/20 0.31
▸ CYP4A11 Q02928 2/20 0.31
▸ PPARG P37231 1/20 0.31
▸ CYP4F2 P78329 1/20 0.31
▸ MEN1 O00255 1/20 0.30
▸ USP2 O75604 1/20 0.30
▸ ALDH1A1 P00352 1/20 0.30
▸ LMNA P02545 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL35211555 0.93 PRKAB2 (0.33) DHODHPRKAB2PRKAG1PRKAA2PRKAA1
SCHEMBL31342626 0.93 PRKAB2 (0.33) DHODHPRKAB2PRKAG1PRKAA2PRKAA1
SCHEMBL31342230 0.93 PRKAB2 (0.33) DHODHPRKAB2PRKAG1PRKAA2PRKAA1
SCHEMBL35212168 0.92 TTR (0.31) RARBTTRALBRARARARG
SCHEMBL31342430 0.91 CYP4A11 (0.39) DHODHTTRCYP4A11CYP4F2PRKCG
SCHEMBL30937306 0.84 DDB1 (0.36) —
SCHEMBL35211910 0.84 CYP4A11 (0.35) DHODHTTRCYP4A11CYP4F2
SCHEMBL35211913 0.84 CYP4A11 (0.35) DHODHTTRCYP4A11CYP4F2
SCHEMBL35211571 0.84 CYP4A11 (0.35) DHODHTTRCYP4A11CYP4F2
SCHEMBL30879998 0.78 AKR1C3 (0.38) DHODHTTRALDH1A1LMNACNR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260124309-A1 STAT6 DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS INC (US) 2026-05-07 — — US disclosed
WO-2025049820-A1 STAT6 DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. (US) 2025-03-06 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260124309-A1 STAT6 DEGRADERS AND USES THEREOF STAT6, NCOR2, NCOR1 DHODH 1599/4885PRKAB2 2436/4885PRKAG1 3458/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback